0001469443-26-000001.txt : 20260127 0001469443-26-000001.hdr.sgml : 20260127 20260126182608 ACCESSION NUMBER: 0001469443-26-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260127 DATE AS OF CHANGE: 20260126 EFFECTIVENESS DATE: 20260127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] ORGANIZATION NAME: 01 Energy & Transportation EIN: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-571201 FILM NUMBER: 26561606 BUSINESS ADDRESS: STREET 1: 5956 SHERRY LANE STREET 2: SUITE 2000 CITY: DALLAS STATE: TX BUSINESS PHONE: 214-974-8921 MAIL ADDRESS: STREET 1: 5956 SHERRY LANE STREET 2: SUITE 2000 CITY: DALLAS STATE: TX D 1 primary_doc.xml X0708 D LIVE 0001469443 Arcadia Biosciences, Inc. 5950 SHERRY LANE SUITE 2000 DALLAS TX TEXAS 75225 214-974-8921 DELAWARE None None Corporation true Thomas J. Schaefer 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Executive Officer Director Kevin Comcowich 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Albert D. Bolles 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Lilian Shackelford Murray 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Gregory D. Waller 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Amy Yoder 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Deborah Carosella 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Other Technology Decline to Disclose 06b false 2026-01-12 false true true true false 0 H.C. Wainwright & Co, LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 NY NEW YORK false 6024289 2082132 3942157 Includes gross proceeds received by company from issuance of shares upon exercise of warrants. Total offering also reflects the aggregate exercise price of inducement preferred investment options issued and placement agent investment options issued. false 3 145749 0 In addition to the cash fee above, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 56,602 shares of common stock at an exercise price of $3.2188 per share 0 false Arcadia Biosciences, Inc. Thomas J. Schaefer Thomas J. Schaefer CEO 2026-01-22